Author(s):
Suvidha S. Mane, Lalita S. Karne, Omkar A . Devade, Laxmikant M. Purane, Vivekkumar K. Redasani
Email(s):
suvidhamane08947@gmail.com
DOI:
10.52711/2321-5836.2025.00007 
Address:
Suvidha S. Mane*, Lalita S. Karne, Omkar A . Devade, Laxmikant M. Purane, Vivekkumar K. Redasani
Department of Pharmacology, YSPM’s Yashoda Technical Campus, Satara 415011, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 1,
Year - 2025
ABSTRACT:
A repeated set of moderate-to-severe behavioural, physical, and affective symptoms that arise during the luteal menstrual cycle and go away a few days after menstruation are known as premenstrual syndrome (PMS). A serious and incapacitating illness that can interfere with social interactions and professional performance is premenstrual dysphoric disorder (PMDD). Premenstrual dysphoric disorder (PMDD) is a condition that affects around 5–8% of women, with the majority of these women also having severe premenstrual syndrome. The most distressing symptoms are those related to mood and behaviour, such as irritability, tension, depression, tearfulness, and mood swings; physical issues, like breast soreness and bloating, can also be problematic. While the exact cause of PMS remains unknown, several theories point to heightened susceptibility to both aberrant neurotransmitter function and typical hormonal fluctuations. Women with PMS can self-report various symptoms and their intensity using the Daily Record of Intensity of Problems, which is a diagnostic tool for the condition. A multidisciplinary team is frequently involved in the step-by-step introduction of treatment, which might include alternative therapies, hormonal and non-hormonal drugs, and even surgery. The pathophysiological theories pertaining to the ailment, aetiology, disease categorization, diagnosis, epidemiology, and recommended management approaches based on guidelines and research are all covered in this review article.
Cite this article:
Suvidha S. Mane, Lalita S. Karne, Omkar A . Devade, Laxmikant M. Purane, Vivekkumar K. Redasani. A Literature Review on Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Research Journal of Pharmacology and Pharmacodynamics. 2025; 17(1):37-6. doi: 10.52711/2321-5836.2025.00007
Cite(Electronic):
Suvidha S. Mane, Lalita S. Karne, Omkar A . Devade, Laxmikant M. Purane, Vivekkumar K. Redasani. A Literature Review on Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Research Journal of Pharmacology and Pharmacodynamics. 2025; 17(1):37-6. doi: 10.52711/2321-5836.2025.00007 Available on: https://rjppd.org/AbstractView.aspx?PID=2025-17-1-7
REFERENCES:
1. Padmavathi P, Kokilavani N. Assess the Effectiveness of Self-Instructional Module on Knowledge of Premenstrual Syndrome among Adolescent Girls in Selected Area, Erode. Asian Journal of Nursing Education and Research. 2013; 3(3):164-6.
2. Joseph N, Poonely L, Alice NC. Prevalence of premenstrual syndrome and knowledge regarding premenstrual syndrome and its management among girls. Asian Journal of Nursing Education and Research. 2022; 12(3): 283-8 10.52711/2349-2996.2022.00060
3. Kessel B. Premenstrual syndrome. Obstetrics and Gynaecology Clinics of North America. 2000 Sept; 27(3): 625–39. Doi:10.1016/s0889- 8545(05)70160-1
4. Chung SH, Kim TH, Lee HH, Lee A, Jeon DS, Park J, Kim Y. Premenstrual syndrome and premenstrual dysphoric disorder in perimenopausal women. Journal of Menopausal Medicine. 2014 Aug;20(2):69.
5. Halbreich U, O’Brien PS, Eriksson E, Bäckström T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/ premenstrual dysphoric disorder? CNS Drugs. 2006 Jul; 20:523- 47.
6. Frye GM, Silverman SD. Is it premenstrual syndrome? Keys to focused diagnosis, therapies for multiple symptoms. Postgraduate Medicine. 2000 Jan 1; 107(5): 151-9.
7. Silva CM, Gigante DP, Carret ML, Fassa AG. Population study of premenstrual syndrome. Revista de Saúde Pública. 2006; 40:47-56. doi:10.1590/s0034-89102006000100009
8. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. American Journal of Obstetrics and Gynaecology. 2003 May 1; 188(5): S56-65.doi:10.1067/mob.2003.403
9. American Psychiatric Association. Diagnostic and statistical Manual of Mental Disorders. 2022 Mar 18; Doi: 10.1176/appi.books.9780890425787
10. Rajamani S. A Study to assess the effectiveness of structured teaching programme on knowledge regarding premenstrual syndrome and its coping strategies among adolescence girls of selected school of Ratia. Asian Journal of Nursing Education and Research. 2021; 11(1): 107-12. DOI: 10.5958/2349-2996.2021.00028.8
11. Frank RT. The hormonal causes of premenstrual tension. Archives of Neurology and Psychiatry. 1931 Nov 1; 26(5): 1053. doi:10.1001/archneurpsyc.1931.02230110151009
12. Schiola A, Lowin J, Patel R. The burden of moderate/severe premenstrual syndrome and premenstrual dysphoric disorder in a cohort of Latin American women. Value in Health. 2011 Jul; 14(5). Doi: 10.1016/j.jval.2011.05.008
13. Futterman LA. Advances in the diagnosis of premenstrual syndrome and premenstrual dysphoric disorder. Expert Opinion on Medical Diagnostics. 2009 Dec 15; 4(1): 91–8. doi: 10.1517/17530050903431418
14. Yonkers KA, O’Brien PS. Premenstrual syndrome. The Lancet. 2008 Apr; 371(9619): 1200–10. doi:10.1016/s0140-6736(08)60527-9
15. Adewuya AO, Loto OM, Adewumi TA. Pattern and correlates of premenstrual symptomatology amongst Nigerian university students. Journal of Psychosomatic Obstetrics & amp; Gynecology. 2009 Jan; 30(2): 127–32. doi:10.1080/01674820802545446
16. Direkvand-Moghadam A, Sayehmiri K, Delpisheh A, Kaikhavandi S. Epidemiology of premenstrual syndrome (PMS)-a systematic review and meta-analysis study. Journal of Clinical and Diagnostic Research: JCDR. 2014 Feb; 8(2): 106.
17. Lee AM, So-Kum Tang C, Chong C. A culturally sensitive study of premenstrual and menstrual symptoms among Chinese women. Journal of Psychosomatic Obstetrics, Gynecology. 2009 Jan; 30(2): 105–14. doi:10.1080/01674820902789241
18. Schmidt PJ, Danaceau MA, Rubinow DR. Differential behavioural effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine. 1998 Jan 22; 338(4): 209–16.doi:10.1056/nejm199801223380401
19. Pakharenko LV. Effect of estrogen receptor gene ESR1 polymorphism on development of premenstrual syndrome. Reproductive Health of Woman. 2020 Jul 31; 1: 5–8. doi:10.30841/2708-8731.1.2020.471239
20. Lustyk MK, Gerrish WG. Premenstrual syndrome and premenstrual dysphoric disorder: Issues of quality of life, stress and exercise. Handbook of Disease Burdens and Quality of Life Measures. 2010; 1951–75. doi:10.1007/978-0-387-78665-0_115
21. Kaur J, Kaur J, Kaur K, Kaur JS, Kaur K, Singh L, Kaur L, Kaur M, Kaur AS, Kaur BS, Kaur HS. Effectiveness of planned teaching programme on knowledge regarding life style changes in prevention of pre-menstrual syndrome among adolescent girls in a selected school at Dehlon, Ludhiana. International Journal of Nursing Education and Research. 2016; 4(3): 327-39.
22. Pearlstein T, Yonkers KA, Fayyad R. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of Affective Disorders. 2005 Apr; 85(3): 275–82. doi: 10.1016/j.jad.2004.10.004
23. Spinelli MG. Depression and hormone therapy. Clinical Obstetrics and Gynecology. 2004 Jun 1;47(2):428-36.
24. Hunter MS, Ussher JM, Cariss M, Browne S, Jelley R, Katz M. Medical (fluoxetine) and psychological (cognitive–behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. Journal of Psychosomatic Research. 2002 Sep1; 53(3): 8117.
25. Gnanasambanthan S, Datta S. Premenstrual syndrome. Obstetrics, Gynaecology & Reproductive Medicine. 2019 Oct 1; 29(10): 2815.
26. Kadian S, O'Brien S. Classification of premenstrual disorders as proposed by the International Society for Premenstrual Disorders. Menopause International. 2012 Jun; 18(2): 43-7.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders.Text Revision. 2000.
28. Dennerstein L, Lehert P, Bäckström TC, Heinemann K. Premenstrual symptoms–severity,duration and typology: an international cross-sectional study. Menopause International. 2009 Sep; 15(3): 120-6.
29. Padmavathi P, Sankar R, Kokilavani N, Dhanapal K, Ashok B. Validity and reliability study of premenstrual syndrome scale (PMSS). Int J Adv Nurs Manag. 2014 Jan; 2(1): 4-10.
30. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. International Clinical Psychopharmacology. 1999 May 1; 14: S27-33.
31. Schechter D, Bachmann GA, Vaitukaitis J, Phillips D, Saperstein D. Perimenstrual symptoms: time course of symptom intensity in relation to endocrinologically defined segments of the menstrual cycle. Psychosomatic Medicine. 1989 Mar 1; 51(2): 173-94.
32. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): Reliability and Validity. Archives
33. Halbreich U, O’Brien PS, Eriksson E, Bäckström T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006 Jul; 20:523-47.
34. Unanyan AL, Arakelov SE, Polonskaya LS, Guriev TD, Morozova VD. Premenstrual syndrome: Current aspects of classification, diagnosis, and treatment. Obstetrics and Gynecology. 2014 Aug 15(8): 133-6.
35. Kessel B. Premenstrual syndrome: Advances in diagnosis and treatment. Obstetrics and Gynecology Clinics of North America. 2000 Sep 1; 27(3):625-39.
36. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetricians- gynecologists: premenstrual syndrome. ACOG Practice Bulletin. 2000; 15.
37. Condon JT. The premenstrual syndrome: a twin study. The British Journal of Psychiatry.1993 Apr; 162(4):481-6.
38. Kendler KS, Silberg JL, Neale MC, Kessler RC, Heath AC, Eaves LJ. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychological Medicine. 1992 Feb; 22(1): 85-100.
39. Wood C, Larsen L, Williams R. Social and psychological factors in relation to premenstrual tension and menstrual pain. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1979 May;19(2):111-5.
40. Hallman J. The premenstrual syndrome–an equivalent of depression? Acta Psychiatric Scandinavica. 1986 Apr; 73(4): 403-11.
41. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study: XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. European Archives of Psychiatry and Clinical Neuroscience. 1993 Jul; 243: 23-32.
42. Warner P, Bancroft J. Factors related to self-reporting of the pre-menstrual syndrome. The British Journal of Psychiatry. 1990 Aug 1; 157(2): 249-60.
43. Pearlstein T, Stone AB. Premenstrual syndrome. Psychiatric Clinics of North America.1998 Sep 1; 21(3): 577-90.
44. Malik R, Bhat MD. The management of Premenstrual syndrome: A review. Bangladesh Journal of Medical Science. 2018; 17(1): 16.
45. Pathak K, Udapi G. A Study to Assess the Knowledge Regarding Psychological Problems of Premenstrual Syndrome and its Management among Adolescent girls at Selected PU College of Belgaum City, with a View to Develop Informational Booklet. Asian Journal of Nursing Education and Research. 2017; 7(1): 9-11.
46. Sharmila P, Prince V. Descriptive study to assess the knowledge of Premenstrual Syndrome and its management among I year B. Sc. nursing students in Bishop's College of nursing, Dharapuram. International Journal of Nursing Education and Research. 2017; 5(4):392-4.
47. Panay N. Management of premenstrual syndrome: evidence-based guidelines. Obstetrics, Gynaecology & Reproductive Medicine. 2011 Aug 1; 21(8):221-8.
48. Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. American Family Physician. 2002 Oct 1; 66(7): 123949.
49. Zinder, Dar. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiological Scandinavica. 1999 Nov; 167(3): 181-8.
50. McCabe D, Lisy K, Lockwood C, Colbeck M. The impact of essential fatty acid, B vitamins, vitamin C, Magnesium and zinc supplementation on stress levels in women: a systematic review. JBI Evidence Synthesis. 2017 Feb 1; 15(2): 402-53.
51. Rapkin A. A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder. Psych neuroendocrinology. 2003 Aug 1; 28: 39-53.
52. Malik R, Bhat MD. Premenstrual syndrome and its historical perspective. International Journal of Advanced Complementary and Traditional Medicine. 2016 Dec 31; 2(1): 16-23.
53. Nalini R, Jocob J. Effectiveness of reflexology on premenstrual syndrome among students. International Journal of Advances in Nursing Management. 2015; 3(2): 139-44.
54. Alvir JM, Thys-Jacobs S. Premenstrual and menstrual symptom clusters and response to calcium treatment. Psychopharmacology Bulletin. 1991 Jan 1;27(2):145-8.
55. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. Journal of Women's Health. 1998 Nov; 7(9): 1157-65.
56. Chan PD, Johnson SM. Current Clinical Strategies Gynecology and Obstetrics. 2006.
57. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson Calcium and vitamin D intake and risk of incident premenstrual syndrome. Archives of Internal Medicine. 2005 Jun 13; 165(11): 1246-52.
58. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. Journal of Psychiatry and Neuroscience. 2000 Nov; 25(5): 459.
59. Bendich A. The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms. Journal of the American College of Nutrition. 2000 Feb 1; 19(1): 3-12.
60. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Alternative Therapies in Health and Medicine. 2001 Sep 1; 7(5): 70.
61. Tamborini A, Taurelle R. Value of standardized Ginkgo biloba extract (EGb 761) in the management of congestive symptoms of premenstrual syndrome. Revue Francaise De Gynecologie et D'obstetrique. 1993 Jul 1; 88(7-9): 447-57.
62. Ozgoli G, Selselei EA, Mojab F, Majd HA. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. The Journal of Alternative and Complementary Medicine. 2009 Aug 1; 15(8): 845-51.
63. Imai A, Ichigo S, Matsunami K, Takagi H. Premenstrual syndrome: management and pathophysiology, Clin Exp Obstet Gynecol. 2015; 42(2): 123-8.
64. Schellenberg R. Treatment for the premenstrual syndrome with Agnus castus fruit extract: prospective, randomised, placebo-controlled study. Bmj. 2001 Jan 20; 322(7279): 134-7.
65. Ahsan M, Mallick AK. The effect of soy isoflavones on the menopause rating scale scoring in perimenopausal and postmenopausal women: A pilot study. Journal of Clinical and Diagnostic Research: JCDR. 2017 Sep; 11(9): FC13. doi:10.7860/JCDR/2017/26034.10654
66. Shanees E. A Study to determine the effectiveness of Ginger candy on Premenstrual syndrome among college girls in selected colleges, Satna. International Journal of Nursing Education and Research. 2019; 7(4): 512-6. DOI: 10.5958/2454-2660.2019.00113.3
67. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomedicine & Pharmacotherapy. 2002 Aug 1; 56(6): 283-8.
68. Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews. 2013(6).
69. J. Cunningham, K.A. Yonkers, S. O’Brien, E. Eriksson, Update on research and treatment of premenstrual dysphoric disorder, Harv. Rev. Psychiatry. 2009; 17: 120–137.
70. Dimmock PW, Wyatt KM, Jones PW, O'Brien PS. Efficacy of selective serotonin- reuptake inhibitors in premenstrual syndrome: a systematic review. The Lancet. 2000 Sep 30; 356(9236):1131-6.
71. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstetrics & Gynecology. 2008 May 1;111(5):1175-82.
72. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics & Gynecology. 2005 Sep 1; 106(3):492-501.
73. Bharathi NS, Kayalvizhi E, Sylvia J. Premenstrual syndrome-An overview. International Journal of Nursing Education and Research. 2022;10(4):395-8. 10.52711/2454-2660.2022.00089
74. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual Dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec 1; 72(6): 414-21.
75. Kurshan N, Neill Epperson C. Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Archives of Women's Mental Health. 2006 Jan; 9: 1-4.
76. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews. 2012(2).
77. Nevatte T, O’Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K. ISPMD consensus on the management of premenstrual disorders. Archives of Women's Mental Health. 2013 Aug; 16:279-91.
78. Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. Journal of Women's Health. 2006 Jan 1; 15(1): 57-69.
79. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam: a controlled study. Archives of General Psychiatry. 1990 Mar 1; 47(3): 270-5.
80. Carlini SV, Lanza di Scalea T, McNally ST, Lester J, Deligiannidis KM. Management of premenstrual dysphoric disorder: a scoping review. International Journal of Women's Health. 2022 Dec 31: 1783-801.
81. Dimmock PW, Wyatt KM, Jones PW, O'Brien PS. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. The Lancet. 2000 Sep 30; 356(9236): 1131-6. doi.org/10.1016/S0140-6736(00)02754-9.
82. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics & Gynecology. 2005 Sep 1; 106(3): 492-501. DOI: 10.1097/01.AOG.0000175834.77215.2e
83. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec 1; 72(6):414-21. doi.org/10.1016/j.contraception.2005.08.021
84. Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. Journal of Women's Health. 2006 Jan 1; 15(1): 57-69. doi.org/10.1089/jwh.2006.15.57.
85. Freeman EW, Sondheimer SJ, Polansky M, Garcia-Espagna B. Predictors of response to sertraline treatment of severe premenstrual syndromes. Journal of Clinical Psychiatry. 2000 Aug 8; 61(8): 579-84.
86. Halbreich U, O’Brien PS, Eriksson E, Bäckström T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006 Jul; 20: 523-47.
87. Jefferson JW. Psychotropic medications and their effects on sexual function. The Journal of Clinical Psychiatry. 1995 Nov 1; 56(11): 536-7.
88. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women Contraception. 2007 May 1; 75(5): 328-36. doi.org/10.1016/j.contraception.2006.12.018.
89. Dinger JC, Heinemann LA. European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903]. BMC Women's Health. 2006 wDec; 6: 1-7. doi:10.1186/1472-6874-6-1.
90. Rapkin AJ, McDonald M, Winer SA. Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder. Women’s Health. 2007 Jul; 3(4): 395-408. doi.org/10.2217/17455057.3.4.395